Eveline Pasman is a prominent physician-scientist and entrepreneur noted for her pioneering work in medical innovation. As a co-founder and Chief Operating Officer of Tenomix, she is at the forefront of developing advanced technological solutions aimed at optimizing cancer care and pathology workflows. Pasman’s contributions are instrumental in the realm of medical technology, particularly through Tenomix’s flagship device, Lymphonator, which focuses on enhancing cancer staging procedures. This article delves into ten key insights about Eveline Pasman and her work with Tenomix, showcasing her educational background, career trajectory, and the transformative impact of her innovations in healthcare.
Eveline Pasman holds a Doctor of Medicine (MD) from Radboud University, completed in 2012. She further pursued an interdisciplinary PhD at The University of British Columbia, focusing on Kinesiology, Neuromechanics, Biomechanics, Neuroscience, and Postural Control. Her research concentrated on the neural underpinnings of balance, especially concerning Parkinson's disease, reflecting her commitment to addressing complex medical challenges through scientific inquiry.
In July 2021, Eveline Pasman co-founded Tenomix, a med-tech startup born from the Western University’s Medical Innovation Fellowship program. The company was established with the mission of revolutionizing the way pathology labs process cancer tissues, leveraging her expertise to lead innovations that enhance diagnostic accuracy and healthcare efficiency.
The Lymphonator is a bench-top robotic scanning device designed to automate the detection of lymph nodes in resected cancer tissues, thus improving the efficiency and reliability of cancer staging. By integrating robotics, ultrasound imaging, and AI, this device significantly reduces manual labor in pathology labs and bolsters diagnostic accuracy, making it a groundbreaking innovation in cancer care.
Alongside her role as COO at Tenomix, Eveline Pasman has held several influential positions. These include working as an Interim Director at WORLDiscoveries and as a Medical Innovation Fellow at Western University. Moreover, her early career included hands-on roles as a neurology researcher and resident, which enhanced her understanding of clinical and scientific aspects of healthcare.
Tenomix, under Eveline’s leadership, has garnered substantial recognition. In 2022, the company won the grand prize at the Synapse Life Science Competition, which provided essential funding and support to advance their pioneering technologies. This accolade underscores Eveline’s strategic direction and the company's innovative prowess in medical technology.
The innovations introduced by Eveline Pasman and her team at Tenomix aim to reduce healthcare costs and streamline pathology workflows. The Lymphonator allows for consistent and reliable detection of lymph nodes, minimizing errors in cancer staging, which is crucial for effective treatment planning and patient outcomes.
Eveline’s drive stems from a personal commitment to improving healthcare outcomes. Her work is motivated by a blend of scientific curiosity and a desire to innovate. This passion has consistently guided her towards developing solutions that address unmet needs in the healthcare sector, especially in cancer diagnostics.
Beyond her achievements with Tenomix, Eveline has a history of research contributions, notably in neuroscience and postural control. Her work on identifying brain regions associated with balance offers valuable insights into neurological disorders, contributing to broader medical knowledge and potential therapeutic avenues.
Eveline Pasman’s journey into entrepreneurship was catalyzed by her medical innovation fellowship, which exposed her to the intricacies of medical device development and commercialization. This experience, combined with her scientific background, positioned her effectively to lead a startup like Tenomix focused on transformative healthcare solutions.
Looking ahead, Eveline envisions expanding Tenomix’s technology to address a wider array of cancers beyond colorectal. The integration of advanced imaging and AI capabilities holds the promise to further enhance diagnostic accuracy and workflow efficiency across different types of cancer care settings, marking a significant step in global healthcare advancements.
Eveline Pasman’s work exemplifies the potential of interdisciplinary collaboration and innovative thinking in tackling some of healthcare’s toughest challenges. Through Tenomix and its continuous drive for medical innovation, she is not only advancing cancer diagnostics but also setting a standard for future developments in medical technology. Her journey is a testament to the impact of passion-driven scientific inquiry and strategic entrepreneurship in creating solutions that can fundamentally improve patient care globally.